Glycine Treatment of Prodromal Symptoms

This is an open label trial of the NMDA agonist glycine used alone for symptoms that appear to be prodromal for schizophrenia in adolescents and young adults.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Schizophrenia Mental Disorders Schizophrenia Spectrum and Other Psychotic Disorders

Age range

14 year–35 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

age 14-35
meets SIPS criteria for psychosis prodrome

Exclusion criteria

current antipsychotic medication
more than 4 weeks of antipsychotic medication lifetime

Treatment and study plan

Glycine

Drug

0.8 g/kg/day

Primary outcomes

Scale Of Prodromal Symptoms total score

Time frame: 8 weeks

Sponsors and collaborators

Lead sponsor

Yale University

Other

Collaborators

Stanley Medical Research Institute

Registry information

Important dates

Study start: 2002
Primary completion: 2004
Study completion: 2004
First posted: Dec 22, 2005
Registry last updated: Mar 29, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed